First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome

EAST SETAUKET, NY, July 18, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the first patient has been enrolled in its Phase 1b/2 study of the safety and therapeutic benefit of Lixte’s lead clinical compound, LB-100, in patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) who have failed or are intolerant of standard treatment (NCT03886662).

Dr. John S. Kovach, founder and CEO of Lixte, said “Because there are no standard treatments for patients with refractory MDS, from a statistical standpoint as few as 7 objective responses among the first 47 patients would be considered encouraging and justify proceeding to a Phase 3 trial. Of course, we hope that in the current trial LB-100 will be associated with even higher rates of objective benefit to these patients allowing us to move to Phase 3 before reaching 47 entries.”

The study is open at Moffitt Cancer Center in Tampa, Fla. Dr. Rami Komrokji, vice chair of Moffitt’s Department of Malignant Hematology, is the principal investigator.

About Lixte Biotechnology Holdings, Inc.

Lixte is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and immune checkpoint blockers.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at

Additional information on the Company is available at

Lixte Contact:
(631) 830-7092

Primary Logo

Source: Lixte Biotechnology Holdings, Inc.